Greenleaf Trust Sells 10,451 Shares of Sanofi (NASDAQ:SNY)

Greenleaf Trust trimmed its stake in Sanofi (NASDAQ:SNY) by 56.2% in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 8,136 shares of the company’s stock after selling 10,451 shares during the quarter. Greenleaf Trust’s holdings in Sanofi were worth $405,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently bought and sold shares of the stock. Clearbridge Investments LLC lifted its position in shares of Sanofi by 8.4% in the third quarter. Clearbridge Investments LLC now owns 184,630 shares of the company’s stock valued at $9,904,000 after buying an additional 14,362 shares during the last quarter. Dynamic Advisor Solutions LLC acquired a new stake in shares of Sanofi in the fourth quarter valued at approximately $2,104,000. Soros Fund Management LLC acquired a new stake in shares of Sanofi in the third quarter valued at approximately $11,533,000. International Assets Investment Management LLC acquired a new stake in shares of Sanofi in the fourth quarter valued at approximately $4,704,000. Finally, Clear Street Markets LLC lifted its position in shares of Sanofi by 352.8% in the third quarter. Clear Street Markets LLC now owns 130,183 shares of the company’s stock valued at $6,983,000 after buying an additional 101,430 shares during the last quarter. 10.04% of the stock is currently owned by institutional investors.

Sanofi Stock Performance

NASDAQ:SNY opened at $47.69 on Wednesday. The stock has a market cap of $120.64 billion, a P/E ratio of 20.21, a PEG ratio of 1.65 and a beta of 0.61. The stock has a 50 day simple moving average of $47.58 and a 200 day simple moving average of $48.45. The company has a current ratio of 1.27, a quick ratio of 0.87 and a debt-to-equity ratio of 0.19. Sanofi has a 1-year low of $42.63 and a 1-year high of $57.82.

Sanofi (NASDAQ:SNY) last released its quarterly earnings results on Thursday, February 1st. The company reported $0.89 earnings per share for the quarter, missing the consensus estimate of $0.94 by ($0.05). The firm had revenue of $11.76 billion for the quarter, compared to analyst estimates of $13.02 billion. Sanofi had a return on equity of 27.47% and a net margin of 12.56%. Research analysts anticipate that Sanofi will post 4.11 earnings per share for the current year.

Sanofi Increases Dividend

The business also recently disclosed an annual dividend, which will be paid on Thursday, June 6th. Shareholders of record on Friday, May 10th will be paid a dividend of $1.478 per share. This represents a yield of 2.98%. The ex-dividend date is Thursday, May 9th. This is a positive change from Sanofi’s previous annual dividend of $1.38. Sanofi’s dividend payout ratio (DPR) is 58.47%.

Analysts Set New Price Targets

A number of research firms have recently issued reports on SNY. Morgan Stanley began coverage on Sanofi in a research report on Tuesday, January 23rd. They issued an “equal weight” rating and a $55.00 price objective for the company. StockNews.com cut Sanofi from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, February 27th. Finally, TheStreet cut Sanofi from a “b” rating to a “c” rating in a report on Friday, February 9th. One analyst has rated the stock with a sell rating, three have issued a hold rating and three have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and a consensus price target of $55.00.

About Sanofi

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.